CFM
RLMD icon

Catalyst Funds Management’s Relmada Therapeutics RLMD Stock Holding History

Catalyst Funds Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,057
Closed -$237K – 849
2026
Q1 		$237K Buy
+34,057
New +$161K 0.04% 424
2024
Q2 		– Sell
-4,290
Closed -$19.9K – 1525
2024
Q1 		$19.9K Buy
+4,290
New +$20.7K 0.01% 760

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Catalyst Funds Management's RLMD Position: Q2 2026 in Review

Catalyst Funds Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 34,057 shares — an estimated $237K sold.

Catalyst Funds Management first reported a position in RLMD in Q1 2024 and held it in 2 quarters. The position peaked at $237K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Catalyst Funds Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 34,057 Relmada Therapeutics shares in Q2 2026, an estimated $237K.
  • Catalyst Funds Management first reported a position in Relmada Therapeutics in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Relmada Therapeutics position peaked at $237K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.